StockData

Precigen vs Verastem

PGEN and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PGEN and VSTM compare

Precigen is the larger company, worth 2.3 times as much as Verastem ($1.5B against $671M).

Verastem scores higher on the StockData Score (3 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPGENVSTM
Size and price
Market cap$1.5B$671M
Share price$4.29$7.41
Change, 1 year−11.5%−1.9%
Change, 5 years11.1%−77.0%
Beta (5Y)1.202.66
Employees20102
StockData Score
Total score23 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S–7.7×
P/B35.2×13.4× (better)
FCF yield−7.5%–
Growth
Revenue growth, 5Y average−21.3%−19.0% (better)
Profitability
Operating margin–−183%
Net margin–−232%
Return on equity−4640%−471% (better)
Financial health
Debt / equity2.15–
Interest coverage–−108.3×
Current ratio4.58 (better)2.25
Altman Z-score−11.14−7.37 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.2%109%
Held by insiders44.9%1.8%
Insider net buying, 12 months−$32.5M−$816K (better)
Superinvestors holding1–
Short interest, % of float22.8%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.